24. Đặc điểm hội chứng viêm đa cơ quan liên quan Covid-19 ở trẻ em (mis-c) tại Bệnh viện Đa khoa Xanh Pôn

Abstract

This is a prospective descriptive study designed to evaluate clinical features, laboratory characteristics and treatment outcomes of COVID-19-related multi-system inflammatory syndrome in children (MIS-C) at Saint Paul General Hospital. The study was conducted on 33 pediatric patients who were diagnosed with MIS-C and treated between March 2022 and August 2022. The average age of the research group was 5.48 years old, with the highest incidence observed in the 2–12-year-old age group (48.5%). The male to female ratio was 1.75:1. The time to develop MIS-C symptoms from onset of COVID-19 was 1-12 weeks, with a median of 4 weeks. The most common clinical symptoms observed were fever (100%), rash (72.7%), red eye (39.4%), and edema (42.4%). The mean time of fever before treatment was 4.03 ± 1.74 days. The laboratory characteristics showed that 75.76% had a decreased number of lymphocytes, all of children have increased levels of CRP. Systemic inflammatory response was observed in the majority of pediatric patients with 90.63% having increased D-dimer, 80% having increased Ferritin, and 100% having increased LDH. Some cardiac injuries were noted, including pericardial effusion (25.8%), mitral valve regurgitation (22.6%), and reduced ejection fraction (12.9%). In terms of severity, the majority of children with MIS-C were mild (69.7%), while the remaining cases met the Kawasaki criteria or had severe MIS-C in equal proportions (15.15%). All patients received corticosteroid therapy, and one-third received IVIG. The hospital stay ranged from 2 to 17 days, with an average of 7 days and there was no reported death among the patients.